Summary of Creatinol O-Phosphate
Primary Information, Benefits, Effects, and Important Facts
Creatinol O-Phosphate (COP) is a synthetic analogue of creatine that was created as a cardioprotective drug, and it appears to be helpful against arrythmia and aid the integrity of cardiac tissue following injections of up to three grams. Via this method of administration and dosage, it appears to be safe as well as effective.
A lack of information exists on COP oral ingestion and whether the benefits translate from oral to injections. Additionally, all research appears to be a few decades old and has since just ceased for unknown reasons; a weird thing for such a promising compound (unless another cardioprotective agent was deemed safer and more effective, making injections of COP for clinical usage not needed to be researched anymore).
Due to the lack of pharmacokinetic data, it is hard to ascertain the benefits associated with COP ingestion. If absorbed, it will be cardioprotective and safe. Optimal dosing regimen is not known at this time due to no bioavailability data.
For all intents and purposes, COP supplementation should be viewed as completely different as creatine supplementation. Even after COP loses the phosphorus group, it metabolizes into creatinol and not creatine.
No fake reviews. No selling you supplements. Just evidence-based information on what works
Our free supplement mini-course teaches you what works, what's a waste, and how to achieve your health goals.
Join the over 200,000 people who have gone through this course (saving themselves time and millions of dollars).
How to Take Creatinol O-Phosphate
Recommended dosage, active amounts, other details
Past studies used injections of up to 3g daily. There is currently no bioavailability data on how much is absorbed, but if it is 100% then this is the dose where benefits have been noted in humans.
Get access to the latest research
By becoming an Examine.com Member, you'll have access to all of the latest nutrition research on over 300 supplements across over 500 different health goals, outcomes, conditions, and more.
Scientific Research on Creatinol O-Phosphate
Click on any below to expand the corresponding section. Click on to collapse it.
Creatinol O-Phosphate (also known as Creatinolphosphate or Aplodan), sometimes abbreviated as COP, is a cardioprotective drug that appears to have been well researched a few decades ago and has since had a lack of recent studies.
The name of the molecular structure in full is N-methyl-N-(beta-hydroxyethyl)guanidine O-phosphate. The molecule of COP is different than that of the phosphorylated form of creatine, as the phosphate group is attached to a different segment of the creatine molecule. COP has not yet been shown to carry the traditional benefits of creatine supplementation, and for practical purposes should be seen as a different molecule.
100umol/L of COP can invoke a positive ionotropic effect that is glucose dependent and a slight negative chronotropic effect when oxygen is in the range of normoxia, and helped the recovery of cardiac contractility after ischemia (lack of oxygen) which is thought to be via a glycolytic mechanism.
One study that used isoprenaline (beta-adrenergic agonist) in a dose that was able to induce cardiac lesions noted that pretreatment of 200mg/kg COP (injections) was able to significantly attenuate the degree of cardiac lesions and doses up to 1000mg/kg have been shown to dose-dependently reduce death induced by an overdose of isoprenaline in mice (16% reduction at 250mg/kg, 50% reduction at 1000mg/kg). Low doses can increase in efficacy over 4 days of loading when compared to the same dose taken 4 hours acutely prior to the isoprenaline insult, and these effects may occur in a rehabilitative manner as evidence by 3060mg of Creatinol O-Phosphate given for three days (IV) to persons who recently suffered a Myocardial infarction, where serum cardiac enzymes decreased by 33-46% relative to control.
Injections of Creatinol O-Phosphate have an apparent cardioprotective effect against beta-adrenergic induced lesions and may possibly be rehabilitative as well; no studies on oral ingestion at this time
A reduction in the time required for atropine to induce cardiac arrythmia in guinea pigs has also been noted. Anti-arrythmic properties have been noted in vivo with COP supplementation even after three days of 2040mg (twice daily 1020mg injections).
Administration of COP, as well as the reference drug atropine, have been shown to improve A-V conduction of the heart in a small sample (n=6) pilot study; atropine's benefits were more evidence.
Injections of COP appear to be beneficial for arrythmia disturbances, no studies on oral ingestion
In rats, injections of up to 1000mg/kg appear to not be associated with death acutely
In otherwise healthy humans, intravenous doses of up to 3060mg COP failed to alter Arterial pressure, heart rate, ECG pattern, or all aspects aside from phosphorus levels (which increased following 2040-3060mg) in a blood panel; an increase in urinary phosphorus and diuresis also resulted with no overt signs of toxicity.
Currently appears to be safe following injections of up to around 3g, no studies conducted on oral administration
- Godfraind T, Saleh MM. Action of creatinol-O-phosphate on the contractility changes evoked by hypoxia and ischemia in rat isolated heart. Arzneimittelforschung. (1984)
- Marzo A, Ghirardi P. Pharmacological and toxicological properties of creatinol O-phosphate. A review. Arzneimittelforschung. (1979)
- Godfraind T, Sturbois X. The prevention by creatinol O-phosphate of myocardial lesions evoked by isoprenaline. Arch Int Pharmacodyn Ther. (1979)
- Ferrini R, Miragoli G. Protective effect of creatinol O-phosphate (COP) on some experimental arrhythmias in vitro and in vivo. Arzneimittelforschung. (1979)
- Godfraind T, Sturbois X. An analysis of the reduction by creatinol O-phosphate of the myocardial lesions evoked by isoprenaline in the rat. Arzneimittelforschung. (1979)
- Knippel M, Bana G, Pusterla GL. Effects of creatinol O-phosphate on serum enzymes in acute myocardial infarction. Arzneimittelforschung. (1979)
- Di Maio F, et al. Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial. Arzneimittelforschung. (1979)
- Cadel A, et al. Antiarrhythmic effectiveness of creatinol O-phosphate in man. Arzneimittelforschung. (1979)
- Botti G, Bonatti V. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneimittelforschung. (1979)
- Melloni GF, et al. Acute clinical tolerance of creatinol O-phosphate. Arzneimittelforschung. (1979)